Dr. Roopa Viswanathan, has been in practice for over 22 years and is Founder and MD of Qualilife Diagnostics, a NABL accredited, ICMR and DGHS approved laboratory based in Mulund, Mumbai. Previously, she led the Microbiology Department in Bombay Hospital and held the position of Clinical Microbiologist and Infection Control Officer for the Ministry of Health, Brunei Darussalam. She has also achieved FRC Path from the UK and is currently an Infection Control Consultant for multiple hospitals in Mumbai, as well as Consultant for Unilever, specifically for their clinical trials, hygiene products portfolio. She is a founding member of the Society of clinical microbiologists and executive committee member of the TPA and HIS (Mumbai forum). She is also a member of the Ethics Committee and Bio-safety Committee of various institutions and has many publications to her credit in peer reviewed National and International Journals. She is a keen academian, being a reader at Yerla Dental College.
“The LumiraDx Platform is very intuitive. When validated in my lab, we realized that it was easy to use, precise, accurate, with little scope for error and provides a result comparable to lab reference instruments.”
Dr. Roopa Viswanathan
Qualilife Diagnostics offers state of the art services for the diagnosis of infectious diseases, with biosafety and quality assurance compliances. It is a well-equipped laboratory, with technology and personnel expertise to meet any infectious diseases diagnostics related challenges. Qualilife Diagnostics vision is to expand to genetic and molecular level diagnostics in the quest for the targeted and tailor-made management of critical illnesses.
We have been using the LumiraDx Platform with non-COVID testing, D-Dimer and INR assays since March 2022. This unique technology, which gives similar results to lab reference instruments gives us the confidence to use it in our lab and to report with reliance.
Until LumiraDx representatives delivered the concept of their innovative patented microfluidic technology, the term point of care testing (POCT) was just another lateral flow test to us. We then went on to validating the LumiraDx SARS-CoV-2 Ag Test against RT-PCR. The results obtained were comparable and we recommend its use as a COVID Ag screening test.
Dr. Roopa Viswanathan Iyer, MD Microbiologist, Chief Microbiologist and Managing Director of Qualilife Diagnostics and Joint Director of Qualilife Brain and Spine LLP.
‘Women Empowerment Principles Leadership 2021-2022’ by ET Now
Supporting healthier lives, for individuals, communities and wider society.
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.